Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A flat illustration of a diagnostic test kit and reagent drop in a minimalist style.

May 21, 2026

Q-Line Biotech IPO Day 1: Issue subscribed over 2x, NIIs steal the show. Check GMP, issue details

The Q-Line Biotech IPO has made a significant impact on its opening day, with subscriptions exceeding two times the issue size, particularly driven by non-institutional investors (NIIs).Launched on May 21 and set to conclude on May 25, the IPO is priced between ₹326 and ₹343 per share, with a minimum bid for 400 shares. Q-Line Biotech, established in 2010, specializes in the development and distribution of diagnostic reagents, kits, and point-of-care devices, catering to healthcare needs through
A minimalist illustration of a lock and key symbolizing security and investment.

May 21, 2026

Visium Secures Strategic Funding from Top-Tier Investors and Unicorn Founders

Visium, a prominent player in the AI and data sector for regulated industries, has successfully completed its first institutional funding round, attracting support from top-tier investors and notable unicorn founders.Based in Lausanne, Switzerland, Visium has rapidly expanded since its inception in 2018, now employing 100 AI specialists and offering over 250 solutions to major clients in the life sciences sector, including Roche and Novartis. The recent funding round was co-led by Columbus Ventu
Minimalist illustration of an enzyme molecule and a laboratory flask on a dark background.

May 21, 2026

Manchester Imperagen raises €5.8 million Seed to scale AI and quantum-powered enzyme engineering

Imperagen, a biotech firm based in Manchester, has secured €5.8 million in Seed funding to enhance its AI and quantum-powered enzyme engineering capabilities. This investment aims to boost research and development, expand laboratory facilities, and strengthen market entry strategies over the next 18 months.The funding round was spearheaded by PXN Ventures, with contributions from existing investors like IQ Capital and Northern Gritstone, bringing the total capital raised by Imperagen to €9.8 mil
A test tube with an enzyme sample in a laboratory setting.

May 21, 2026

Imperagen Raises $5 Million to Reinvent Enzyme Engineering With AI

Imperagen has successfully secured $5 million in funding to enhance its AI-driven enzyme engineering platform, targeting significant advancements in enzyme design for various industries including pharmaceuticals, agriculture, and industrial biotechnology.The company aims to revolutionize the traditionally slow and costly process of enzyme engineering by integrating artificial intelligence with physics-based simulations and automated lab testing. Its "closed-loop" system leverages machine learnin
A stethoscope on an examination table in a dimly lit room

May 21, 2026

CompuGroup Medical stock (DE000A288904): earnings momentum and digital health ambitions

CompuGroup Medical has unveiled its latest quarterly results, showcasing solid growth and margin improvements, which are particularly relevant for investors interested in the digital health sector.As one of Europe’s prominent healthcare software providers, CompuGroup Medical reported a revenue increase to approximately EUR 305 million for Q1 2026, up from EUR 290 million in the same period last year. This growth reflects the company's strategic focus on enhancing efficiency and developing softwa
A stethoscope on a medical chart in a dimly lit consultation room

May 21, 2026

Digital health shakeout accelerates as investors back fewer, bigger players

The digital health landscape is undergoing a significant transformation, marked by a contraction in investment and a shift towards consolidation in Australia and globally. A recent report from Galen Growth indicates that venture capital funding for digital health dropped to $7.1 billion across 216 deals in Q1 2026, reflecting a 6.6% year-on-year decline. This trend is characterized by fewer but larger investments, with the average deal size increasing by 87% to $38.4 million.Emma Hossack, CEO of
A drug compound on a lab surface with a molecular model behind it.

May 21, 2026

Incyte stock (US45337C1027): AI collaboration and stock moves draw attention

Incyte is gaining attention due to recent developments involving an AI collaboration and notable trading activity, providing investors with fresh insights into this biotech firm.The renewed focus on Incyte stems from its expanded collaboration with Genesis Molecular, which introduces a technological dimension to its established drug discovery and commercialization efforts. This partnership signals Incyte's commitment to enhancing its research productivity, a critical factor in the biotech sector
Vial of RNA editing compound on a lab table

May 21, 2026

Wave Life Sciences (WVE) Is Down 11.4% After Positive WVE-006 AATD Data and Accelerated Path Update

Wave Life Sciences has experienced an 11.4% decline in its stock following the release of promising data for its RNA editing candidate, WVE-006, which shows potential in treating alpha-1 antitrypsin deficiency (AATD). The latest Phase 1b/2a RestorAATion-2 trial results indicate that WVE-006 effectively reduces harmful Z-AAT levels while restoring protective M-AAT, all through convenient subcutaneous dosing and a favorable safety profile.Investors may find the multidose cohorts particularly notew
Flat illustration of an enzyme structure with quantum wave representation

May 21, 2026

Imperagen raises £5 million to use quantum physics, AI on enzyme engineering

Imperagen, a biotech startup focused on enzyme engineering, has successfully secured £5 million ($6.7 million) in seed funding, primarily from PXN Ventures, along with contributions from IQ Capital and Northern Gritstone. Established in 2021 by scientists from the Manchester Institute of Biotechnology, the company aims to revolutionize enzyme engineering by leveraging advanced technologies.To enhance the enzyme engineering process, Imperagen is adopting a novel approach that integrates quantum p
A glass vial containing an enzyme sample on a lab bench in a dimly lit laboratory.

May 21, 2026

Spin-out Imperagen raises £5m and announces new CEO

Imperagen, a Manchester-based life sciences spin-out, has successfully secured £5 million in seed funding to enhance its enzyme engineering capabilities through AI and quantum physics technologies.The funding round, led by PXN Ventures and supported by existing investors IQ Capital and Northern Gritstone, brings Imperagen's total funding to £8.5 million. This capital will enable the company to expand its research and development efforts, enhance its wet lab capabilities, and strengthen its marke
A prostate biopsy needle and sample in a clinical setting.

May 21, 2026

Prostate Cancer Diagnostics Market to Reach US$ 14.83 Billion by 2034 Amid Rising Cancer Awareness

The prostate cancer diagnostics market is on a robust growth trajectory, anticipated to expand from US$ 8.12 billion in 2025 to US$ 14.83 billion by 2034, reflecting a compound annual growth rate (CAGR) of 6.92% from 2026 to 2034. This growth is largely driven by heightened awareness of prostate cancer, government-supported screening initiatives, and advancements in diagnostic technologies.The increasing incidence of prostate cancer, particularly among men over 50, is a significant factor fuelin
A molecular diagnostics instrument in a dimly lit lab setting, surrounded by glassware and research tools.

May 21, 2026

Revvity stock (US76155R1086): life science player after Q1 update and new AI lab tools

Revvity has recently provided its Q1 2026 financial update, showcasing its commitment to expanding its portfolio of life science tools, particularly through the integration of AI technologies in lab software.In its latest earnings report, Revvity emphasized ongoing investments in diagnostics and life science tools, highlighting advancements in AI-supported lab solutions. The company aims to enhance its offerings in molecular diagnostics and research tools, positioning itself as a significant pla